Unlocking disease insights to facilitate drug development: Pharmaceutical industry–academia collaborations in inflammation and immunology

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-03-01 DOI:10.1016/j.drudis.2025.104317

Elena Peeva , Emma Guttman-Yassky , Yuji Yamaguchi , Brian Berman , Barry Oemar , Jyoti Ramakrishna , Alessio Fasano , Carmella Evans-Molina , Myron Chu , Benjamin Ungar , Percio S. Gulko , Maria Padilla , Roberta Weiss , Arezou Khosroshahi , Patrick M. Brunner , Marguerite Meariman , Michael S. Vincent , Mikael Dolsten

{"title":"Unlocking disease insights to facilitate drug development: Pharmaceutical industry–academia collaborations in inflammation and immunology","authors":"Elena Peeva , Emma Guttman-Yassky , Yuji Yamaguchi , Brian Berman , Barry Oemar , Jyoti Ramakrishna , Alessio Fasano , Carmella Evans-Molina , Myron Chu , Benjamin Ungar , Percio S. Gulko , Maria Padilla , Roberta Weiss , Arezou Khosroshahi , Patrick M. Brunner , Marguerite Meariman , Michael S. Vincent , Mikael Dolsten","doi":"10.1016/j.drudis.2025.104317","DOIUrl":null,"url":null,"abstract":"<div><div>Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and pathophysiological investigations. This review highlights key collaborations between Pfizer and academic institutions in inflammation and immunology research, including dermatology, gastroenterology, rheumatology, and autoimmunity. These collaborations harness and enhance the development of innovative disease models, large clinical databases, registries, and novel clinical trial designs, and open new avenues in disease management to improve patient outcomes.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 3","pages":"Article 104317"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625000303","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and pathophysiological investigations. This review highlights key collaborations between Pfizer and academic institutions in inflammation and immunology research, including dermatology, gastroenterology, rheumatology, and autoimmunity. These collaborations harness and enhance the development of innovative disease models, large clinical databases, registries, and novel clinical trial designs, and open new avenues in disease management to improve patient outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.